# PTBP1 protects Y RNA from cleavage leading to its apoptosis-specific degradation

**Authors:** Takeshi Kamakura, Kazuaki Kameda, Masahiko Manabe, Kan Torii, Yuki Sugiura, Seiko Ito, Shunya Nakayama, Takanobu Shimizu, Etsuko Nagashima, Kosuke Kamiya, Masahiro Oka, Masafumi Tanaka, Motoyuki Otsuka, Masato Ohtsuka, Ai Kotani

PMC · DOI: 10.1038/s41420-024-02080-6 · Cell Death Discovery · 2024-07-12

## TL;DR

This study shows that PTBP1 protects Y RNA from being cut during cell death, and its loss leads to immune issues and autoantibodies.

## Contribution

The study reveals a novel role of PTBP1 in protecting Y RNA from cleavage during apoptosis and links this process to autoimmune disease.

## Key findings

- PTBP1 inhibits Y RNA cleavage during apoptosis by acting as an endoribonuclease inhibitor.
- Caspase 3-resistant PTBP1 mutant prevents Y RNA cleavage and reduces autoantibody formation in mice.
- Dysregulation of Y RNA cleavage is linked to immune dysfunction and autoimmune disease development.

## Abstract

Some RNAs such as 28S rRNA, U1 small nuclear RNA (snRNA), and Y RNAs are known to be cleaved during apoptosis. The underlying mechanism, functions, and biological significance of RNA degradation in apoptosis remain elusive. Y RNAs are non-coding RNAs widely conserved from bacteria to mammals, and are major components of Ro ribonucleoprotein (RNP) complexes which contain the 60 kDa Ro protein (SS-A) and the 50 kDa La protein (SS-B). The autoantigenic Ro and La proteins were identified by autoantibodies present in the sera from patients with Systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SjS). We previously identified novel, functional small RNAs named AGO-taxis small RNAs (ASRs) that are specifically bound to Argonaute protein 1 (AGO1), which are processed from Y RNAs. Cell-free analysis combined with fractionation methods revealed that the apoptosis-specific biogenesis of ASRs or cleavage of Y RNA was induced by truncation of polypyrimidine tract-binding protein 1 (PTBP1), which is an endoribonuclease inhibitor of Y RNAs by caspase 3. Caspase 3-resistant PTBP1 mutant protected cleavage of Y RNAs in apoptosis induced by staurosporine. Furthermore, caspase 3-resistant PTBP1 mutant knock-in mice showed elevated cytokines, dysregulation of the germinal center formation compared to the wild-type mice at LPS stimulation, and high positivity of antinuclear antibody. Those results suggest that cleavage of Y RNAs or biogenesis of ASR during apoptosis has critical biological functions and their deregulation result in immune dysregulation and the formation of autoantibody, possibly leading to the development of autoimmune diseases.

## Linked entities

- **Genes:** PTBP1 (polypyrimidine tract binding protein 1) [NCBI Gene 5725], AGO1 (argonaute RISC component 1) [NCBI Gene 26523], Casp3 (caspase 3) [NCBI Gene 12367]
- **Chemicals:** staurosporine (PubChem CID 5279)

## Full-text entities

- **Genes:** TRIM21 (tripartite motif containing 21) [NCBI Gene 6737] {aka RNF81, RO52, Ro/SSA, SSA, SSA1, TRIM21/Ro52}, SSB (small RNA binding exonuclease protection factor La) [NCBI Gene 6741] {aka LARP3, La, La/SSB, SSB/La}, PTBP1 (polypyrimidine tract binding protein 1) [NCBI Gene 5725] {aka HNRNP-I, HNRNPI, HNRPI, PTB, PTB-1, PTB-T}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, AGO1 (argonaute RISC component 1) [NCBI Gene 26523] {aka EIF2C, EIF2C1, GERP95, NEDLBAS, Q99, hAgo1}
- **Diseases:** SLE (MESH:D008180), SjS (MESH:D012859), autoimmune diseases (MESH:D001327), immune dysregulation (OMIM:614878)
- **Chemicals:** LPS (MESH:D008070), staurosporine (MESH:D019311)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11245482/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11245482/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC11245482/full.md

---
Source: https://tomesphere.com/paper/PMC11245482